Gines Escolar

170 Villarroel Street
Barcelona, CT 08036, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 104 publications

Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresis.

Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresis.

Journal: Frontiers in immunology

Published: April 10, 2026

Common Biomarkers of Endothelial Dysfunction Across Highly Prevalent Diseases with Cardiovascular Risk: Functional Characterization and Prognostic Implications.

Common Biomarkers of Endothelial Dysfunction Across Highly Prevalent Diseases with Cardiovascular Risk: Functional Characterization and Prognostic Implications.

Journal: International journal of molecular sciences

Published: March 11, 2026

Impaired hemostasis in mechanical circulatory support systems: Monitoring with T-TAS® 01, in vitro correction with VWF concentrates, and impact of membrane oxygenators.

Impaired hemostasis in mechanical circulatory support systems: Monitoring with T-TAS® 01, in vitro correction with VWF concentrates, and impact of membrane oxygenators.

Journal: Heart & lung : the journal of critical care

Published: February 16, 2026

Diagnostic performance of flow cytometric osmotic fragility testing in hereditary spherocytosis.

Diagnostic performance of flow cytometric osmotic fragility testing in hereditary spherocytosis.

Journal: Cytometry. Part B, Clinical cytometry

Published: February 15, 2026

In Vitro Evidence of Therapy-Induced Suppression of Prothrombotic and Proinflammatory Phenotypes in Severe COVID-19.

In Vitro Evidence of Therapy-Induced Suppression of Prothrombotic and Proinflammatory Phenotypes in Severe COVID-19.

Journal: Thrombosis and haemostasis

Published: January 23, 2026

Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.

Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.

Journal: Blood advances

Published: January 15, 2026

EASIX, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura.

EASIX, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura.

Journal: Frontiers in immunology

Published: September 07, 2025

A freeze-dried platelet-derived hemostatic agent improves hemostasis in patients with severe thrombocytopenia before and after standard platelet transfusion: Studies ex vivo in the total thrombus-formation analysis system 01.

A freeze-dried platelet-derived hemostatic agent improves hemostasis in patients with severe thrombocytopenia before and after standard platelet transfusion: Studies ex vivo in the total thrombus-formation analysis system 01.

Journal: Transfusion

Published: September 03, 2025

Budget impact analysis of Haemate-P as long-term prophylaxis and on-demand therapy for von Willebrand disease in Spain.

Budget impact analysis of Haemate-P as long-term prophylaxis and on-demand therapy for von Willebrand disease in Spain.

Journal: Journal of medical economics

Published: July 18, 2025

m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis.

m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis.

Journal: Frontiers in immunology

Published: July 12, 2025

Proteomic profiling links complement activation to thrombosis in JAK2V617F myeloproliferative neoplasms.

Proteomic profiling links complement activation to thrombosis in JAK2V617F myeloproliferative neoplasms.

Journal: Translational oncology

Published: July 03, 2025

Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin Compared With Empagliflozin.

Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin Compared With Empagliflozin.

Journal: Journal of cardiovascular pharmacology

Published: May 30, 2025

Showing 1-12 of 104

Last Updated: 09/26/2026